(VIANEWS) – Halozyme Therapeutics (HALO), Medpace Holdings (MEDP), First Industrial Realty Trust (FR) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Halozyme Therapeutics (HALO)
50.4% sales growth and 146.7% return on equity
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.
Earnings Per Share
As for profitability, Halozyme Therapeutics has a trailing twelve months EPS of $1.87.
PE Ratio
Halozyme Therapeutics has a trailing twelve months price to earnings ratio of 21.4. Meaning, the purchaser of the share is investing $21.4 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 146.7%.
2. Medpace Holdings (MEDP)
17.8% sales growth and 66.57% return on equity
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
Earnings Per Share
As for profitability, Medpace Holdings has a trailing twelve months EPS of $8.53.
PE Ratio
Medpace Holdings has a trailing twelve months price to earnings ratio of 32.35. Meaning, the purchaser of the share is investing $32.35 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 66.57%.
Sales Growth
Medpace Holdings’s sales growth is 26.6% for the ongoing quarter and 17.8% for the next.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Medpace Holdings’s EBITDA is 4.78.
Revenue Growth
Year-on-year quarterly revenue growth grew by 28.3%, now sitting on 1.78B for the twelve trailing months.
3. First Industrial Realty Trust (FR)
10.9% sales growth and 10.92% return on equity
First Industrial Realty Trust, Inc. (NYSE: FR) is a leading fully integrated owner, operator, and developer of industrial real estate with a track record of providing industry-leading customer service to multinational corporations and regional customers. Across major markets in the United States, our local market experts manage, lease, buy, (re)develop, and sell bulk and regional distribution centers, light industrial, and other industrial facility types. In total, we own and have under development approximately 64.1 million square feet of industrial space as of September 30, 2020.
Earnings Per Share
As for profitability, First Industrial Realty Trust has a trailing twelve months EPS of $2.11.
PE Ratio
First Industrial Realty Trust has a trailing twelve months price to earnings ratio of 21.02. Meaning, the purchaser of the share is investing $21.02 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.92%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is a negative 51.6% and a negative 26.2%, respectively.
Earnings Before Interest, Taxes, Depreciation, and Amortization
First Industrial Realty Trust’s EBITDA is 12.94.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Dec 27, 2023, the estimated forward annual dividend rate is 1.28 and the estimated forward annual dividend yield is 3.02%.
Previous days news about First Industrial Realty Trust(FR)
- According to Zacks on Wednesday, 29 November, "This upswing has contributed to the thriving state of the industrial real estate market, which has been proving advantageous for companies like Prologis, STAG Industrial (STAG Quick QuoteSTAG – Free Report) and First Industrial Realty Trust (FR Quick QuoteFR – Free Report) ."
4. Group 1 Automotive (GPI)
7.1% sales growth and 26.94% return on equity
Group 1 Automotive, Inc., through its subsidiaries, operates in the automotive retail industry. The company sells new and used cars, light trucks, and vehicle parts, as well as service and insurance contracts; arranges related vehicle financing; and offers automotive maintenance and repair services. It operates primarily in 17 states in the United States; and 35 towns in the United Kingdom. As of July 11, 2022, the company owned and operated 204 automotive dealerships, 273 franchises, and 47 collision centers that offer 35 brands of automobiles. Group 1 Automotive, Inc. was incorporated in 1995 and is based in Houston, Texas.
Earnings Per Share
As for profitability, Group 1 Automotive has a trailing twelve months EPS of $45.7.
PE Ratio
Group 1 Automotive has a trailing twelve months price to earnings ratio of 6.29. Meaning, the purchaser of the share is investing $6.29 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 26.94%.
Previous days news about Group 1 Automotive(GPI)
- According to Zacks on Wednesday, 29 November, "Backed by multiple new customer wins, such as Greene King Brewing, Group 1 Automotive and the U.S. Department of Energy, it crossed 5,000 customers for its HCM product suite. "
